Standard BioTools Inc.
$0.97
▼
-1.13%
2026-04-21 07:48:01
www.standardbio.com
NMS: LAB
Explore Standard BioTools Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$361.83 M
Current Price
$0.97
52W High / Low
$1.72 / $0.87
Stock P/E
—
Book Value
$1.23
Dividend Yield
—
ROCE
-20.31%
ROE
-13.13%
Face Value
—
EPS
$-0.15
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Devices
Employees
385
Beta
1.42
Debt / Equity
7.27
Current Ratio
4.19
Quick Ratio
4.01
Forward P/E
-29.51
Price / Sales
4.05
Enterprise Value
$188.58 M
EV / EBITDA
-2.29
EV / Revenue
2.21
Rating
None
Target Price
$1.55
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | 908 Devices Inc. | $7.3 | 13.73 | $267.64 M | — | -16.46% | -25.77% | $9.34 / $4.2 | $3.96 |
| 2. | Artivion, Inc. | $38.8 | 193.48 | $1.89 B | — | 3.41% | 2.7% | $48.25 / $22.22 | $9.37 |
| 3. | STERIS plc | $223.73 | 31.17 | $21.95 B | 1.11% | 10.53% | 10.47% | $269.44 / $209.98 | $72.93 |
| 4. | Cytek Biosciences, Inc. | $4.57 | — | $592.62 M | — | -10.52% | -18.05% | $6.18 / $2.37 | $2.66 |
| 5. | Medtronic plc | $83.14 | 23.25 | $107.11 B | 3.34% | 8.3% | 9.39% | $106.33 / $79.93 | $38.17 |
| 6. | Quanterix Corporation | $3.3 | — | $164.29 M | — | -31.92% | -34.25% | $8.77 / $3.23 | $6.33 |
| 7. | SI-BONE, Inc. | $14.32 | — | $632.45 M | — | -10.47% | -10.97% | $21.89 / $12.15 | $4.07 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 23.8 M | 19.55 M | 21.76 M | 40.8 M | 46.72 M | — |
| Operating Profit | -21.92 M | -23.47 M | -23.7 M | -30.29 M | -29.74 M | — |
| Net Profit | 19.28 M | -34.69 M | -33.46 M | -26.03 M | -34.07 M | — |
| EPS in Rs | 0.05 | -0.09 | -0.09 | -0.07 | -0.09 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 85.33 M | 91.01 M | 106.34 M | 97.95 M |
| Operating Profit | -93.31 M | -87.01 M | -63.04 M | -102.62 M |
| Net Profit | -74.9 M | -138.88 M | -74.66 M | -190.1 M |
| EPS in Rs | -0.19 | -0.36 | -0.19 | -0.49 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 567.75 M | 612.35 M | 323.07 M | 390.31 M |
| Total Liabilities | 143.46 M | 140.62 M | 471.12 M | 471.78 M |
| Equity | 424.29 M | 471.72 M | -148.05 M | -81.47 M |
| Current Assets | 454.26 M | 375.88 M | 158.22 M | 208.81 M |
| Current Liabilities | 108.31 M | 65.89 M | 109.33 M | 43.44 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -74.34 M | -143.45 M | -43.29 M | -89.37 M |
| Investing CF | 27.41 M | 363.17 M | 20.24 M | -88.13 M |
| Financing CF | 0.57 M | -102.62 M | -6.81 M | 230.76 M |
| Free CF | -82.65 M | -151.81 M | -46.12 M | -93.19 M |
| Capex | -8.3 M | -8.36 M | -2.83 M | -3.83 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -14.42% | 8.57% | — | — |
| Earnings Growth % | -86.03% | 60.73% | — | — |
| Profit Margin % | -152.61% | -70.21% | -194.08% | — |
| Operating Margin % | -95.6% | -59.28% | -104.77% | — |
| Gross Margin % | 49.32% | 47.44% | 37.83% | — |
| EBITDA Margin % | -77.16% | -51.21% | -177.21% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.